FDA approves generic versions of Novartis epilepsy drug

Share this article:

The FDA has approved the first generic versions of Novartis' epilepsy treatment Trileptal (oxcarbazepine).

Roxane Laboratories, Sun Pharmaceuticals and Glenmark Pharmaceuticals won approval to sell versions of oxcarbazepine in three strengths – 150 mgs 300 mgs, and 600 mgs.

US sales of Trileptal were $549 million in 2006.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions